Since my last coverage , Pfizer (NYSE: PFE ) has remained relatively stable, while the S&P 500 declined by 2.25%, a reflection of its defensive attractiveness in a risk-off environment. Its bull case is centered in its core pharma growth, expanding beyond pandemicYiannis Zourmpanos, founder of Yiazou IQ, an AI-driven stock research platform providing all-in-one stock reports. Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certified Accou ...

Pfizer’s (PFE) stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past couple of years due to declining sales of its COVID products with the end of the pandemic.After witnessing possibly its worst slowdown in 2023/2024, the company seems to be gradually making a comeback and entering a transition phase. Its non-COVID drugs and contributions from new and newly acquired products have started t ...

Group 1 - The article is the first in a series of comparative analyses between two pharmaceutical companies, with plans to publish one article each week over the next four weeks [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical companies [2] - The company aims to simplify investment strategies for both seasoned and novice investors, fostering a community of informed investors [2] - Allka Research seeks to share its insights through Seeking Alpha, contributing analyses and perspectives to empower financial decision-making [2]

When it comes to dividend investing, some are adamant that dividends don't matter but are just the removal of value from the company's share price. Instead, they think that selling shares to create your own synthetic dividendContributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do thei ...

If you want to generate significant long-term gains in the stock market, one place to start looking for investments is among the companies that Wall Street isn't all that thrilled with today. In the short term, these may not be good performers, and they may not have looked like great buys in recent months or years. But there can be winners to be found among cheaply valued stocks. The trick is to pick out the diamonds in the rough that have a lot of upside potential in the long run.Verizon Communications (VZ ...

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the discount bin. However, even in a bull market, like the one we're currently experiencing, it's possible to find attractive companies to invest in at attractive prices.For that, look no further than the pharmaceutical giant Pfizer (PFE -1.43%). The drugmaker has significantly lagged the market in the past three years. But at its current levels, Pfizer might be a steal for long-term investors. ...

In my last article about Pfizer Inc. (NYSE: PFE ), I argued that the low price and high dividend might offset the expanding risks. In the meantime, an investment would have returned about 5% and although this does not seem likeMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization ...

Core Viewpoint - Pfizer's CEO Albert Bourla indicated that the company may consider relocating drug manufacturing back to the US if tariffs imposed by President Trump impact operations [1][7]. Group 1: Manufacturing Operations - Pfizer currently operates 13 manufacturing sites in the US, with some being large-scale facilities [2]. - The company has the capability to transfer manufacturing from overseas sites to US sites if necessary [2]. - Bourla emphasized that the US manufacturing sites are currently operating at good capacity [2]. Group 2: Political Context - Bourla expressed that he was not surprised by Trump's election victory, noting it was a significant win [3]. - He acknowledged that the new administration presents both risks and opportunities for the pharmaceutical industry [3]. - The company aims to maintain close relations with the administration to influence the regulatory environment [3]. Group 3: Tariff Implications - Trump announced plans to impose 25% tariffs on Mexico and Canada, which could affect Pfizer's operations [4]. - The Trump administration previously imposed a 10% tariff on China, with an additional 10% set to take effect soon [5]. - Bourla stated that Pfizer does not currently rely on China, Canada, or Mexico for its operations [5].

Group 1: Pfizer - Pfizer's shares have declined approximately 57% from their peak in late 2021, primarily due to faster-than-expected declines in COVID-19 product sales and upcoming patent cliffs for top-selling products [3][4] - Despite the stock price drop, Pfizer has maintained its dividend payout, raising it for the 16th consecutive year, resulting in a substantial 6.6% dividend yield at recent prices [3][7] - In 2024, sales of the blood thinner Eliquis grew by 9% to $7.4 billion, accounting for 11.6% of total revenue, but generic versions are expected to launch in 2028, which may significantly impact revenue [4][7] - Pfizer's total revenue rose by 7% last year, and excluding declining COVID-19 product sales, total sales surged by 12% year over year [7] - The FDA approved nine new drugs from Pfizer's pipeline in 2023, with more than a dozen approvals granted in 2024, indicating a strong development pipeline to offset future losses [6][7] Group 2: UnitedHealth Group - UnitedHealth Group's shares have decreased by about 25% from their peak in November 2022, driven by unexpectedly high healthcare utilization rates that negatively impacted profits [8] - Medical costs rose by 9% in 2024, while total revenue only increased by 6%, leading to a significant 35% decline in net income to $15.51 per share [8] - The company has the ability to raise premiums to maintain profitability, as options in the insurance industry have become limited due to consolidation [9] - UnitedHealth Group employs 90,000 physicians through its Optum Health division, which represents roughly 10% of the total physician workforce in the U.S., allowing for better control over medical expenses [10][11] - Despite the stock price decline, UnitedHealth Group has increased its dividend payout by 94% over the past five years, although the current yield is only 0.4% [12]

Acquisition and Growth Strategy - The company anticipates significant benefits from the December 2023 acquisition of Seagen, which is expected to enhance its product pipeline and market position[22]. - Anticipated capital spending and capital allocation frameworks are being developed to support future growth and operational needs[22]. - The company aims to strategically capitalize on growth opportunities by advancing its product pipeline and maximizing the value of existing products[36]. - The company actively engages in business development activities to strengthen its business and generate growth through potential transactions[36]. - The company is focused on emerging markets, recognizing their potential growth opportunities due to urbanization and the rise of the middle class[57]. Cost Management and Operational Efficiency - The company launched the Realigning our Cost Base Program in October 2023, aiming to optimize operational efficiency and reduce costs[22]. - The Manufacturing Optimization Program announced in May 2024 is designed to lower the cost of goods sold, contributing to improved profitability[22]. - The company is focused on improving R&D productivity and maximizing operational efficiency as part of its core business principles[37]. Research and Development - The company is committed to ongoing research and development efforts, with expectations for new product candidates and regulatory submissions in the pipeline[22]. - The company’s R&D priorities focus on oncology, internal medicine (including cardiovascular and migraine), vaccines, and inflammation and immunology[45]. - Pfizer's R&D pipeline includes numerous projects at various stages, with the drug discovery process often taking over ten years[50]. - Pfizer's investment in R&D is multi-billion dollars, aimed at maintaining a strong and differentiated product pipeline[78]. - Pfizer's R&D operations are being consolidated into a single organization effective January 1, 2025, aimed at improving productivity and efficiency[47]. Market Dynamics and Competition - The company is addressing potential pricing pressures and competition from generics and biosimilars, which may affect revenue[22]. - The company faces risks related to competition from new product entrants, generic products, and biosimilars[32]. - Increased competition from generics and biosimilars is anticipated, particularly in markets like China, leading to potential price cuts and volume loss[82]. - Pricing pressures in the commercial sector are significant, with private payors challenging pharmaceutical pricing, which may result in lower prices and reduced demand[86]. Regulatory Environment - The company is actively managing risks related to regulatory approvals and market dynamics that could impact product availability and commercial potential[22]. - The company is subject to extensive government regulation, which includes compliance costs and potential legal actions for non-compliance[94]. - The FDA regulates pre- and post-marketing activities related to biopharmaceutical products, impacting the approval and marketing processes[95]. - The U.S. government is expected to continue regulating pharmaceutical pricing and access, which may lead to legislative changes affecting the business[108]. - The EU is undergoing a comprehensive overhaul of pharmaceutical legislation, which could impact approval procedures and regulatory data protection[112]. Environmental and Sustainability Initiatives - The company is focused on greenhouse gas emission reduction goals as part of its sustainability initiatives[22]. - Pfizer aims to reduce greenhouse gas emissions by 95% and value chain emissions by 90% from 2019 levels by 2040[123]. - In 2024, Pfizer incurred $100 million in environmental-related capital expenditures and $174 million in other environmental-related expenses[121]. Workforce Management and Employee Engagement - As of December 31, 2024, Pfizer employed approximately 81,000 people worldwide, emphasizing a people-centric approach to workforce management[125]. - Pfizer emphasizes the importance of continuous learning and skill-building for colleagues to enhance engagement and productivity[132]. - The company promotes a variety of growth opportunities, including diagonal moves and temporary projects, to foster a resilient workforce[132]. - Pfizer's commitment to health and safety includes comprehensive EHS training and regular workplace assessments to mitigate risks[134]. - The company offers a range of wellness services, including on-site health clinics and mental health resources, to support colleague well-being[135]. - Pfizer is dedicated to pay equity, conducting annual assessments to ensure equitable pay practices based on various factors[136]. - The company is focused on maintaining a motivated workforce through equitable pay practices and ongoing development opportunities[136]. Financial Performance and Revenue Trends - The company projects ongoing impacts from COVID-19 on its business, including expected revenue fluctuations and demand seasonality for certain products[22]. - In 2024, Pfizer's international operations generated revenues of $24.9 billion, accounting for 39% of total revenues, a decrease from 53% in 2023 and 57% in 2022[58]. - The number of countries where revenues exceeded $500 million decreased from 24 in 2022 to 11 in 2024, primarily due to declines in international revenues from Comirnaty and Paxlovid[58]. - The company anticipates a net unfavorable impact to revenue in 2025 of approximately $1 billion year-over-year related to the Medicare Part D redesign changes[104]. - The company continues to seek inclusion of its major products on MCO formularies, although branded products are increasingly placed on higher tiers or non-preferred status[92].